Johnson & Johnson (JNJ.US) files for new domestic indications for heavyweight products.

According to the information obtained from the Wise Finance APP, on August 22, the official website of the CDE showed that the new indication application for Johnson & Johnson's Nilarabitol tablets (JNJ.US) has been accepted. Based on public information and clinical progress, it is speculated that the indication for this marketing application is hormone-dependent prostate cancer.